TW201910349A - 包含重組人類cd38細胞外區域之組合物、方法及/或套組 - Google Patents

包含重組人類cd38細胞外區域之組合物、方法及/或套組 Download PDF

Info

Publication number
TW201910349A
TW201910349A TW107119019A TW107119019A TW201910349A TW 201910349 A TW201910349 A TW 201910349A TW 107119019 A TW107119019 A TW 107119019A TW 107119019 A TW107119019 A TW 107119019A TW 201910349 A TW201910349 A TW 201910349A
Authority
TW
Taiwan
Prior art keywords
aforementioned
tag
seq
region
antibody
Prior art date
Application number
TW107119019A
Other languages
English (en)
Chinese (zh)
Inventor
約翰A 霍爾
彼得 施溫德
喬迪 貝瑞
文森索 法瓦洛羅
伊莉莎白 布斯
馬泰奧 賓達
Original Assignee
美商格里佛診斷方法股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商格里佛診斷方法股份有限公司 filed Critical 美商格里佛診斷方法股份有限公司
Publication of TW201910349A publication Critical patent/TW201910349A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107119019A 2017-08-10 2018-06-01 包含重組人類cd38細胞外區域之組合物、方法及/或套組 TW201910349A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10
US62/543,788 2017-08-10

Publications (1)

Publication Number Publication Date
TW201910349A true TW201910349A (zh) 2019-03-16

Family

ID=62846219

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107119019A TW201910349A (zh) 2017-08-10 2018-06-01 包含重組人類cd38細胞外區域之組合物、方法及/或套組

Country Status (18)

Country Link
US (3) US11708418B2 (https=)
EP (3) EP3587445B1 (https=)
JP (3) JP6833851B2 (https=)
KR (2) KR102631281B1 (https=)
CN (2) CN117820498A (https=)
AR (1) AR112357A1 (https=)
AU (2) AU2018313028B2 (https=)
BR (1) BR112020002636A2 (https=)
CA (1) CA3070789A1 (https=)
EA (1) EA202090265A1 (https=)
ES (2) ES2911243T3 (https=)
HU (1) HUE065510T2 (https=)
MX (3) MX2020001489A (https=)
PL (1) PL3587445T3 (https=)
PT (1) PT3587445T (https=)
TW (1) TW201910349A (https=)
UY (1) UY37757A (https=)
WO (1) WO2019030581A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke
US11746140B2 (en) * 2018-02-20 2023-09-05 F. Hoffman-La Roche Ag Composition comprising recombinant GPlbα receptor protein
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
JP6649941B2 (ja) * 2015-02-16 2020-02-19 株式会社ファーマフーズ Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤
US9944679B2 (en) * 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗EphA4抗体
AU2016352676A1 (en) * 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38
HUE065510T2 (hu) * 2017-08-10 2024-05-28 Grifols Diagnostic Solutions Inc Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke

Also Published As

Publication number Publication date
JP7289328B2 (ja) 2023-06-09
CN109790210B (zh) 2024-03-26
EP3464343A1 (en) 2019-04-10
JP2021088567A (ja) 2021-06-10
JP2019527533A (ja) 2019-10-03
MX2024008109A (es) 2024-07-19
CA3070789A1 (en) 2019-02-14
AR112357A1 (es) 2019-10-23
US11708418B2 (en) 2023-07-25
KR20240015159A (ko) 2024-02-02
JP2023041802A (ja) 2023-03-24
MX2024005669A (es) 2024-05-30
CN117820498A (zh) 2024-04-05
US20240132616A1 (en) 2024-04-25
EP4296680A2 (en) 2023-12-27
EP4296680A3 (en) 2024-03-20
EP3587445A1 (en) 2020-01-01
BR112020002636A2 (pt) 2020-07-28
EA202090265A1 (ru) 2020-06-05
AU2023204121B2 (en) 2026-04-23
PL3587445T3 (pl) 2024-04-29
HUE065510T2 (hu) 2024-05-28
AU2018313028B2 (en) 2023-05-25
AU2023204121A1 (en) 2023-07-20
ES2911243T3 (es) 2022-05-18
PT3587445T (pt) 2024-03-14
EP3464343B1 (en) 2022-03-23
JP6833851B2 (ja) 2021-02-24
ES2973864T3 (es) 2024-06-24
CN109790210A (zh) 2019-05-21
KR20200035194A (ko) 2020-04-02
WO2019030581A1 (en) 2019-02-14
MX2020001489A (es) 2020-03-20
EP3587445B1 (en) 2023-12-13
UY37757A (es) 2018-11-30
US20240092929A1 (en) 2024-03-21
US20210198376A1 (en) 2021-07-01
KR102631281B1 (ko) 2024-01-30
AU2018313028A1 (en) 2020-02-20
US20240228651A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
AU2023204121B2 (en) Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
King et al. Eosin‐5‐maleimide binding to band 3 and Rh‐related proteins forms the basis of a screening test for hereditary spherocytosis
US8618247B2 (en) Peptide, use of the peptide, method for the production of the peptide, solid support having the peptide immobilized thereon, and method for production of the solid support
EP3855186A2 (en) A method for determining the efficacy of a sars-cov-2 vaccine
JP7561775B2 (ja) 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための方法及び試薬
JP7847587B2 (ja) 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための多量体
JP2023514270A (ja) 免疫グロブリン検出と関連する療法
JP2019527033A5 (https=)
Cressey et al. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients
BR122024021835A2 (pt) Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão.
BR122024021803A2 (pt) Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão
WO2011068538A2 (en) General method for generating ultra-high affinity binding proteins
Sakamoto et al. Characterization of feline serum ferritin-binding proteins: the presence of a novel ferritin-binding protein as an inhibitory factor in feline ferritin immunoassay
Gnann et al. Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach